STOCKROUTINES

GlaxoSmithKline plc

Last Updated
Share Price
$44.39
Market Cap
$112.84B
Dividend Yield
N/A
EPS
$2.52
P/E
17.6

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

0%
Income
  • Revenue £34.11B
  • Gross Profit £22.51B
  • Net Income £4.38B
  • Gross Margin 65.99%
  • Net Margin 12.85%
Cash Flow
  • Free Cash Flow (FCF) £5.02B
  • Free Cash Flow To Equity (FCFE) £3.03B
  • Dividends Paid £-4B
  • Debt Repayment £-2B
  • Net Stock Repurchased £-21M
Balance Sheet
  • Shareholder Equity £15.05B
  • Debt To Equity (D/E) 383.67%
  • Book Value £21.34B
  • Book Value Per Share (BVPS) £0
  • Return On Invested Capital (ROIC) 14.77%
The financial metrics for GlaxoSmithKline plc presented below are for the financial year 2021.
P/E 25.16 Price To Earnings Ratio
P/S 3.23 Price To Sales Ratio
P/B 5.17 Price To Book Ratio
P/CF 13.87 Price To Operating Cash Flow Ratio
P/FCF 21.97 Price To Free Cash Flow Ratio
P/FCFE 36.46 Price To Levered Free Cash Flow Ratio
P/EBT 20.27 Price To Pre-Tax Income
PEG -0.91 Trailing Price/Earnings To Growth Ratio
EV/Sales 3.82 Enterprise Value To Sales Ratio
EBIT/EV 0.04 EBIT To Enterprise Value Ratio
EV/EBITDA 16.2 Enterprise Value to EBITDA Ratio
D/E 3.84 Debt To Equity Ratio
ROE 29.59% Return On Equity
ROIC 14.77% Return On Invested Capital
DPR 91.2% Dividend Payout Ratio
Current Ratio 0.79 Current Liquidity Ratio
EPS Growth -27.57% Earnings Per Share Growth Rate
Graham Number $18.34 Benjamin Graham's Number
Piotroski Score N/A Piotroski F-Score
Beta N/A Beta Coefficient Value
    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986
Revenue £34.11B£34.1B£33.75B£30.82B£30.19B£27.89B£23.92B£23.01B£26.5B£26.43B£27.39B£28.39B£28.37B£24.35B£22.74B£23.22B£21.66B£20.35B£21.41B£21.21B£20.53B£18.08B£8.49B£7.98B£7.98B£8.34B£10.49B£6.48B£5.66B£4.93B£4.1B£3.4B£3.18B£2.57B£2.06B£1.74B£1.43B
Cost of Revenue £11.6B£11.7B£11.86B£10.24B£10.34B£9.29B£8.85B£7.32B£8.59B£7.89B£7.33B£7.59B£7.38B£6.42B£5.21B£5.01B£4.76B£4.31B£4.54B£4.61B£4.44B£3.96B£4.33B£1.54B£0£0£0£904.11M£0£0£0£0£0£0£0£0£0
Gross Profit £22.51B£22.39B£21.89B£20.58B£19.84B£18.6B£15.07B£15.68B£17.92B£18.54B£20.05B£20.8B£20.99B£17.94B£17.53B£18.21B£16.89B£16.04B£16.88B£16.6B£16.09B£14.12B£4.16B£6.44B£0£0£0£5.58B£0£0£0£0£0£0£0£0£0
Gross Profit Margin 65.99%65.68%64.85%66.77%65.74%66.69%62.99%68.17%67.61%70.13%73.23%73.26%73.98%73.66%77.08%78.43%78%78.84%78.81%78.27%78.38%78.09%48.95%80.65%0%0%0%86.05%0%0%0%0%0%0%0%0%0%
Operating Expenses £16.31B£16.17B£15.6B£13.52B£13.78B£12.57B£12.44B£11.38B£12.02B£12.37B£12.84B£17.02B£12.56B£10.8B£9.33B£10.4B£16.53B£9.9B£10.49B£9.91B£9.99B£10.7B£1.36B£3.78B£5.08B£5.21B£6.92B£4.12B£3.84B£3.41B£2.8B£3.4B£3.18B£2.57B£2.06B£1.74B£1.43B
Research & Development Expenses (R&D) £5.28B£5.1B£4.57B£3.89B£4.48B£3.63B£3.56B£3.45B£3.92B£3.97B£4.01B£4.46B£4.11B£3.68B£3.24B£3.46B£3.14B£2.84B£2.79B£2.9B£2.56B£2.53B£1.27B£1.16B£1.15B£1.16B£1.54B£0£858M£739M£595M£475M£420M£323M£230M£149M£113M
Selling, General & Administrative Expenses (SG&A) £10.97B£11.46B£11.4B£9.91B£9.67B£9.37B£9.23B£8.25B£8.48B£8.74B£8.83B£13.05B£9.59B£7.66B£13.64B£14.51B£7.25B£7.06B£7.57B£8.04B£7.47B£0£0£0£0£0£0£3.79B£0£0£0£0£0£0£0£0£0
Other Expenses £57M£-383M£-371M£-292M£-365M£-421M£-350M£-319M£-387M£-336M£0£-493M£-1.14B£-541M£-7.55B£-7.56B£6.14B£0£133.28M£-1.03B£-37.16M£8.17B£88M£2.62B£3.94B£4.05B£5.38B£330.42M£2.98B£2.67B£2.21B£2.92B£2.76B£2.25B£1.83B£1.59B£1.32B
Net Income £4.38B£5.75B£4.64B£3.62B£1.53B£912M£8.42B£2.76B£5.44B£4.57B£5.26B£1.63B£5.53B£4.71B£5.22B£5.39B£4.69B£4.3B£4.48B£3.94B£3.1B£4.16B£1.81B£1.84B£1.85B£2B£1.46B£1.04B£1.3B£1.21B£1.03B£881M£807M£688M£581M£510M£400M
Net Profit Margin 12.85%16.86%13.76%11.75%5.08%3.27%35.2%11.98%20.51%17.27%19.21%5.76%19.5%19.35%22.95%23.2%21.65%21.13%20.91%18.55%15.1%23.02%21.33%23%23.18%23.94%13.9%16.04%22.97%24.48%25.22%25.93%25.39%26.77%28.22%29.29%27.99%
Operating Income £6.2B£7.78B£6.96B£5.48B£4.09B£2.6B£10.32B£3.6B£7.03B£7.39B£7.81B£3.78B£8.43B£7.14B£7.94B£7.81B£363.81M£6.15B£6.38B£5.55B£6.1B£4.73B£2.63B£2.68B£2.82B£3.13B£2.38B£1.45B£1.82B£1.52B£1.29B£0£0£0£0£0£0
Other Income & Expenses (Net) £-759M£-815M£-740M£-683M£-562M£-659M£204M£-629M£-381M£-700M£-109M£-626M£-534M£-482M£-402.39M£-9.19M£6.37B£-31.28M£-62.72M£-45M£-17.89M£1.3B£-50M£-12M£-136M£-168M£5M£62.1M£18M£150M£140M£0£0£0£0£0£0
Depreciation & Amortization £2.52B£2.35B£2.33B£1.86B£1.92B£1.77B£1.63B£1.48B£1.41B£1.45B£1.42B£1.68B£1.56B£1.23B£1.02B£958.04M£903.7M£890.48M£859.04M£824M£812.8M£735M£428M£358M£373M£410M£533M£330.42M£282M£225M£191M£151M£122M£93M£73M£55M£42M
Interest Income £28M£29M£98M£81M£63M£70M£99M£66M£59M£73M£90M£116M£70M£313M£262M£287M£257M£176M£0£73M£0£158M£114M£111M£104M£89M£250M£0£65M£186M£180M£242M£186M£0£0£0£0
Interest Expense £784M£856M£885M£771M£736M£717M£735M£703M£740M£760M£799M£831M£783M£843M£453M£352M£451M£362M£161M£206M£0£317M£206M£202M£227M£276M£337M£0£44M£56M£63M£75M£44M£26M£21M£11M£7M
Income Tax Expense £346M£580M£953M£754M£1.36B£877M£2.15B£137M£1.02B£1.95B£2.24B£1.3B£2.22B£1.95B£2.22B£2.3B£1.92B£1.7B£1.74B£1.46B£1.65B£1.75B£746M£815M£819M£933M£867M£476.61M£524M£461M£386M£359M£357M£316M£256M£245M£209M
Effective Tax Rate 6.36%8.32%15.32%15.71%38.47%45.23%20.46%4.62%15.33%29.11%29.1%41.31%28.16%29.24%29.47%29.51%28.46%27.8%27.47%26.53%27.12%28.98%28.97%30.51%30.49%31.48%36.32%31.44%28.56%27.52%27.05%27.98%30.2%31.41%30.77%32.84%34.15%
EBITDA £8.04B£9.54B£8.82B£7B£5.55B£4.28B£12.94B£5.08B£8.61B£8.72B£9.72B£5.45B£10.1B£8.73B£8.92B£9B£7.96B£7.25B£7.23B£6.43B£5.56B£6.96B£3.19B£3.21B£3.27B£3.62B£3.19B£1.85B£2.15B£1.95B£1.67B£1.47B£1.33B£1.12B£931M£821M£658M
EBIT £5.51B£7.18B£6.48B£5.15B£3.62B£2.51B£11.31B£3.6B£7.2B£7.27B£8.3B£3.77B£8.54B£7.5B£7.89B£8.04B£7.05B£6.36B£6.38B£5.6B£4.75B£6.23B£2.76B£2.85B£2.9B£3.21B£2.66B£1.52B£1.87B£1.72B£1.48B£1.31B£1.21B£1.03B£858M£766M£616M
EBT N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Shares Outstanding 2.5B2.49B2.47B2.46B2.44B2.43B2.42B2.4B2.42B2.46B2.51B2.55B2.53B2.62B2.76B2.82B2.84B2.87B2.9B2.96B3.04B3.03B1.81B1.8B1.78B1.76B1.64B1.58B1.52B1.51B1.51B1.5B1.5B744.86M740M740M740M
Diluted Shares Outstanding 2.53B2.52B2.51B2.49B2.47B2.45B2.44B2.43B2.46B2.49B2.55B2.56B2.55B2.63B2.78B2.85B2.86B2.87B2.92B2.98B3.06B3.07B1.82B1.82B1.8B1.76B1.64B1.58B1.52B1.51B1.51B1.5B1.5B744.86M740M740M740M
EPS £1.75£2.31£1.88£1.47£0.63£0.38£3.49£1.15£2.25£1.86£2.09£0.64£2.18£1.8£1.89£1.91£1.65£1.36£1.54£1.32£1.01£1.35£1£1.02£1.04£1.13£0.89£0.66£0.85£0.8£0.69£0.59£0.54£0.92£0.79£0.69£0.54
Diluted EPS £1.73£2.28£1.85£1.46£0.62£0.37£3.45£1.13£2.21£1.83£2.06£0.64£2.16£1.79£1.87£1.89£1.64£1.36£1.54£1.32£1£1.34£1£1.01£1.02£1.13£0.89£0.66£0.85£0.8£0.69£0.59£0.54£0.92£0.79£0.69£0.54
    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1995 1994 1993 1992 1991
Operating Cash Flow £7.95B£8.44B£8.02B£8.42B£6.92B£6.5B£2.57B£5.18B£7.22B£4.38B£6.25B£6.8B£7.84B£7.21B£6.17B£4.36B£5.96B£4.7B£4.85B£3.06B£4.61B£1.85B£510M£410M£615M£849M£1.25B£2.45B£1.05B£927M£657M£615M
Net Income £4.38B£5.75B£4.64B£3.62B£1.53B£912M£8.42B£2.76B£5.44B£4.57B£5.26B£1.63B£5.53B£4.71B£5.22B£5.39B£4.69B£4.3B£4.48B£3.94B£3.1B£4.16B£1.81B£1.84B£1.85B£2B£1.46B£1.04B£1.3B£1.21B£1.03B£881M
Depreciation & Amortization £2.52B£2.35B£2.33B£1.86B£1.92B£1.77B£1.63B£1.48B£1.41B£1.45B£1.42B£1.68B£1.56B£1.23B£1.02B£958.04M£903.7M£890.48M£859.04M£824M£812.8M£735M£428M£358M£373M£410M£533M£330.42M£282M£225M£191M£151M
Deferred Income Tax £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Stock-Based Compensation £0£381M£365M£360M£333M£319M£368M£332M£319M£220M£198M£179M£179M£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Change In Working Capital £1.26B£2.43B£294M£3.42B£1.69B£3.99B£1.49B£757M£267M£-2.42B£-1.77B£2.78B£-151M£477M£-846.64M£-743.16M£-75.55M£-510.41M£-407.68M£941M£829.32M£297M£-278M£-552M£-207M£-302M£-46M£-60.03M£50M£4M£-73M£-116M
Other Non-Cash Items £-217M£-2.47B£382M£-841M£1.44B£-495M£-9.34B£-153M£-214M£565M£1.14B£528M£720M£785M£771.5M£-1.25B£441.1M£20.85M£-77.84M£-2.64B£-132.83M£-3.34B£-1.45B£-1.23B£-1.4B£-1.26B£-693M£1.14B£-578M£-509M£-494M£-301M
Cash From Investing £-1.78B£2.16B£-5.35B£-1.55B£-1.44B£-1.27B£6.04B£-1.08B£524M£-2.63B£-112M£-1.87B£-4.01B£-1.15B£-3.01B£-1.52B£-1.66B£-1.1B£-938.56M£-1.09B£-2.44B£-484M£-896M£-830M£-657M£-104M£-4.79B£-4.74B£-1.36B£-858M£-372M£-851M
Purchases Of Investments £0£-1M£-258M£-309M£4M£0£-2M£1M£-133M£-229M£-111M£-340M£-183M£-96M£-186M£-69.93M£-23M£-102.71M£-63M£-76M£-46.8M£-1.29B£-428M£-61M£-19M£-25M£-3M£0£-4M£-25M£-6M£0
Sales / Maturities of Investments £0£3.27B£1M£0£64M£683M£357M£205M£15M£224M£1.13B£118M£146M£947M£44.88M£32.16M£35M£57.87M£125M£123M£139.02M£495M£118M£54M£0£3M£37M£0£0£0£0£0
Property, Plant & Equipment Investments £-1.17B£-1.23B£-1.26B£-1.34B£-1.54B£-1.54B£-1.38B£-1.19B£-1.19B£-1.05B£-923M£-1.01B£-1.42B£-1.44B£-2.15B£-1.59B£-902.54M£-864.41M£-868M£-1.23B£-1.12B£-1.1B£-597M£-475M£-415M£-401M£-684M£-485.59M£-575M£-608M£-594M£-606M
Net Acquisitions £185M£3.01B£-3.78B£-292M£356M£592M£7.53B£235M£1.95B£-2.54B£-264M£-354M£-2.79B£-454M£-1.03B£-267.97M£-1.03B£-296.65M£-11.76M£-20M£-849.96M£66M£-29M£-152M£-38M£341M£-6.84B£0£-2M£-3M£0£0
Other Investing Activites £-790M£-2.89B£-52M£392M£-322M£-1B£-466M£-331M£-121M£960M£54M£-278M£234M£-109M£302.48M£374.64M£256.5M£102.19M£-120.8M£111M£-565.73M£1.35B£40M£-196M£-185M£-22M£2.7B£-4.26B£-782M£-222M£228M£-245M
Cash From Financing £-7.59B£-10.13B£-1.84B£-6.39B£-6.38B£-6.39B£-7.1B£-5.38B£-6.27B£-3.35B£-6.23B£-5.57B£-2.77B£-4.91B£-1.74B£-4.79B£-2.91B£-3.93B£-3.94B£-1.57B£-2.78B£-546M£350M£339M£-59M£-658M£3.66B£2.18B£39M£96M£-466M£473M
Debt Repayment £-2B£-7.3B£-4.16B£-2.07B£-3.2B£-919M£-2.41B£-1.71B£-1.87B£-2.56B£-8M£-1.34B£-796M£-3.11B£-207M£-739M£-927M£-422M£0£-631M£0£-756M£-9M£-63M£-504M£-1.25B£-7.29B£0£-1.65B£-1.88B£-1.56B£-1.86B
Dividend Payments £-4B£-3.98B£-3.95B£-3.93B£-3.91B£-4.85B£-3.87B£-3.84B£-3.68B£-3.81B£-3.41B£-3.21B£-3.09B£-3.01B£-2.8B£-2.6B£-2.48B£-2.47B£-2.33B£-2.33B£-2.33B£0£0£0£0£0£0£-844.08M£0£0£0£0
Payout Ratio 91.2%69.18%85.1%108.39%254.96%531.8%46%139.44%67.7%83.55%64.74%196.14%55.9%63.84%53.57%48.2%52.8%57.53%52.03%59.14%75.18%0%0%0%0%0%0%81.22%0%0%0%0%
Net Common Stock Repurchased £-21M£-29M£-51M£-74M£9M£-15M£26M£166M£964M£2.12B£1.93B£-63M£1M£3.65B£3.22B£880.46M£679.38M£1.42B£938M£2.16B£1.59B£-185M£-104M£-284M£-188M£-215M£-106M£-44.08M£-51M£-69M£-24M£-20M
Common Stock Repurchased £0£0£0£0£-65M£-74M£-99M£-333M£-1.55B£-2.53B£-2.23B£-16M£-57M£-3.73B£-3.75B£-1.35B£-999.01M£-1.49B£-978.88M£-2.22B£-1.74B£0£0£0£0£0£0£0£0£0£0£0
Common Stock Issued £-21M£-29M£-51M£-74M£9M£-15M£26M£166M£964M£2.12B£1.93B£-63M£1M£3.65B£3.22B£880.46M£679.38M£1.42B£938M£2.16B£1.59B£-185M£-104M£-284M£-188M£-215M£-106M£-44.08M£-51M£-69M£-24M£-20M
Other Financing Activites £-1.62B£1.12B£6.22B£-469M£735M£-638M£-791M£333M£243M£5.14B£-886M£-1.09B£1.11B£4.86B£4.48B£-574.28M£1.17B£386.03M£-672M£3.56B£1.14B£25M£255M£118M£257M£382M£10.84B£2.98B£1.64B£1.9B£1.07B£2.31B
Accounts Receivables £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Accounts Payables £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Inventory £0£119M£300M£51M£-461M£70M£-111M£-529M£-95M£37M£-157M£238M£-132M£-411M£-457.35M£-298.08M£47.07M£-32.85M£-76.16M£-2M£252.58M£-16M£-391M£-297M£-184M£-96M£8M£44.08M£5M£29M£-47M£-57M
Other Working Capital £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Capital Expenditure (CAPEX) £-2.93B£-2.24B£-2.16B£-1.8B£-2.2B£-2.35B£-1.9B£-1.75B£-1.7B£-1.52B£-1.33B£-1.64B£-1.87B£-2.07B£-2.15B£-1.59B£-902.54M£-864.41M£-868M£-1.23B£-1.12B£-1.1B£-597M£-475M£-415M£-401M£-684M£-485.59M£-575M£-608M£-594M£-606M
Effect Of Foreign Exchange On Cash £-29M£-39M£-82M£8M£-100M£283M£-45M£84M£-148M£-92M£-108M£81M£-158M£1.1B£47.9M£-253.67M£233.05M£0£0£-146M£0£-23M£10M£-30M£-1M£177M£4M£-3.01M£18M£-32M£72M£-9M
Net Change In Cash £-1.44B£431M£744M£487M£-1B£-881M£1.46B£-1.2B£1.32B£-1.7B£-202M£-561M£896M£2.25B£1.46B£-2.21B£1.62B£-335.76M£-26.88M£-893M£-613.21M£799M£-26M£-111M£-102M£264M£119M£2.18B£-253M£133M£-109M£228M
Free Cash Flow (FCF) £5.02B£6.2B£5.86B£6.63B£4.72B£4.14B£668M£3.42B£5.52B£2.85B£4.92B£5.16B£5.97B£5.14B£4.02B£2.77B£5.05B£3.84B£3.98B£1.83B£3.49B£749M£-87M£-65M£200M£448M£568M£1.96B£478M£319M£63M£9M
Free Cash Flow To Equity (FCFE) £3.03B£-1.1B£1.7B£4.56B£1.52B£3.23B£-1.74B£1.72B£3.65B£296M£4.91B£3.82B£5.17B£2.03B£3.81B£2.03B£4.13B£3.41B£3.98B£1.2B£3.49B£-7M£-96M£-128M£-304M£-807M£-6.72B£1.96B£-1.17B£-1.56B£-1.5B£-1.85B
    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2003 2002 2001 2000 1999 1998 1997 1996 1994 1993 1992 1991 1990 1989 1988 1987 1986
Total Assets £79.1B£80.43B£79.69B£58.07B£56.38B£59.08B£53.45B£40.65B£42.09B£41.48B£41.08B£42.23B£42.86B£39.39B£31.03B£25.54B£27.19B£22.57B£23.94B£56.73B£22.33B£21.97B£21.59B£10.43B£9.35B£8.44B£8.31B£7.89B£7.46B£5.68B£5.74B£4.49B£3.47B£2.87B£2.36B£1.8B
Total Current Assets £18.67B£20.25B£19.49B£16.93B£15.91B£16.71B£16.59B£14.68B£15.23B£13.69B£16.17B£16.04B£17.57B£17.27B£13.64B£10.99B£13.17B£13.63B£12.61B£10.28B£10.75B£10.02B£11.27B£6.08B£5.51B£4.8B£4.37B£4.65B£4.44B£3.31B£3.63B£2.86B£2.28B£1.99B£1.66B£1.22B
Cash & Short-Term Investments £4.33B£6.17B£4.79B£3.96B£3.91B£4.99B£5.91B£4.41B£5.6B£4.26B£5.9B£6.33B£6.94B£6.01B£4.54B£3.04B£5.23B£3.98B£3.45B£2.55B£2.47B£2.32B£3.59B£1.97B£1.89B£1.66B£1.26B£2.76B£2.5B£1.75B£2.13B£1.59B£1.29B£1.17B£935M£592M
Cash & Cash Equivalents £4.27B£6.09B£4.71B£3.87B£3.83B£4.9B£5.83B£4.34B£5.53B£4.18B£5.71B£6.06B£6.54B£5.62B£3.38B£2B£4.21B£1.16B£960.96M£1.08B£1.05B£717.82M£1.28B£217M£240M£215M£261M£55M£63M£24M£34M£266M£575M£40M£23M£35M
Short-Term Investments £61M£78M£79M£84M£78M£89M£75M£69M£66M£81M£184M£277M£397M£391M£1.15B£1.03B£1.02B£2.82B£2.49B£1.47B£1.42B£1.6B£2.31B£1.75B£1.65B£1.45B£1B£2.71B£2.43B£1.73B£2.1B£1.33B£719M£1.13B£912M£557M
Net Receivables £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£3.66B£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Inventory £5.78B£6B£5.95B£5.48B£5.56B£5.1B£4.72B£4.23B£3.9B£3.97B£3.87B£3.84B£4.06B£4.06B£3.06B£2.44B£2.18B£2.19B£2.11B£2.08B£2.08B£2.09B£2.28B£1.54B£1.15B£855M£804M£575M£595M£475M£494M£417M£351M£310M£288M£276M
Other Current Assets £8.56B£8.08B£8.76B£7.49B£6.44B£6.62B£5.97B£6.04B£5.73B£5.46B£6.4B£5.87B£6.56B£7.2B£6.04B£5.51B£5.76B£7.46B£7.05B£2B£6.2B£5.6B£5.4B£2.58B£2.47B£2.29B£2.3B£1.31B£1.35B£1.08B£1.01B£855M£637M£503M£434M£353M
Total Non-Current Assets £60.43B£60.18B£60.2B£41.14B£40.47B£42.37B£36.86B£25.97B£26.86B£27.78B£24.91B£26.19B£25.29B£22.12B£17.39B£14.56B£14.02B£8.94B£11.34B£46.45B£11.58B£11.95B£10.32B£4.35B£3.84B£3.63B£3.95B£3.24B£3.02B£2.37B£2.11B£1.63B£1.19B£882M£701M£582M
Property, Plant & Equipment (PP&E) £10.67B£11.01B£11.31B£11.06B£10.86B£10.81B£9.67B£9.05B£8.87B£8.78B£8.75B£9.04B£9.37B£9.68B£7.83B£6.93B£6.65B£6.47B£6.43B£6.86B£6.65B£6.86B£6.64B£3.72B£3.63B£3.58B£3.85B£3.18B£2.96B£2.34B£2.08B£1.61B£1.12B£829M£650M£536M
Goodwill & Intangible Assets £40.63B£40.42B£41.52B£22.99B£23.3B£24.74B£21.83B£12.04B£13.49B£14.52B£11.56B£12.14B£11.54B£7.97B£5.83B£4.05B£4.08B£2.14B£1.84B£38.12B£1.81B£1.85B£1.14B£144M£106M£0£0£0£0£0£0£0£0£0£0£0
Goodwill £10.55B£10.6B£10.56B£5.79B£5.73B£5.96B£5.16B£3.72B£4.21B£4.36B£3.75B£3.61B£3.36B£2.1B£1.37B£757.96M£696M£0£142.8M£18.16B£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Intangible Assets £30.08B£29.82B£30.95B£17.2B£17.56B£18.78B£16.67B£8.32B£9.28B£10.16B£7.8B£8.53B£8.18B£5.87B£4.46B£3.29B£4.08B£2.14B£1.69B£19.96B£1.81B£1.85B£1.14B£144M£106M£0£0£0£0£0£0£0£0£0£0£0
Long-Term Investments £2.15B£3.35B£2.07B£1.47B£1.02B£1.16B£1.39B£1.39B£1.46B£1.28B£966M£1.51B£952M£639M£-308.23M£-298.6M£-386.59M£-2.31B£-2.2B£1.47B£1.7B£0£84M£58M£12M£12M£8M£3M£8M£12M£17M£17M£63M£53M£51M£46M
Other Non-Current Assets £1.75B£1.12B£1.2B£1.73B£1.5B£1.29B£1.06B£804M£956M£817M£794M£930M£1.05B£1.08B£1.84B£1.75B£1.46B£610.01M£5.26B£0£365M£3.23B£1.18B£208M£-154M£-175M£-176M£-3M£-10M£-4M£-23M£-266M£-575M£-40M£-23M£-35M
Other Assets £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Total Liabilities £57.76B£59.62B£61.34B£54.39B£52.89B£54.12B£44.57B£35.72B£34.27B£34.73B£32.25B£32.48B£32.12B£31.07B£21.11B£15.9B£19.62B£16.37B£15.49B£21.94B£14.94B£13.57B£12.63B£7.23B£6.58B£6.55B£7.05B£2.74B£2.8B£2.04B£2.46B£1.69B£1.16B£1.06B£894M£703M
Total Current Liabilities £23.67B£22.15B£24.05B£22.49B£26.57B£19B£13.42B£13.29B£13.68B£13.81B£15.01B£12.79B£12.12B£10.02B£10.36B£7.26B£9.51B£8.72B£8.59B£8.17B£8.81B£9.45B£9.08B£5.26B£4.14B£3.89B£4.15B£2.13B£2.2B£1.57B£2.03B£1.41B£863M£869M£711M£559M
Accounts Payables £17.55B£4.36B£4.14B£3.65B£3.53B£3.6B£3.12B£2.79B£2.74B£2.67B£2.57B£6.89B£6.77B£6.08B£4.87B£864.63M£818.85M£706.44M£684.88M£715M£715M£761.87M£812M£367M£293M£299M£270M£188M£178M£162M£146M£134M£113M£95M£76M£57M
Short-Term Debt £3.6B£3.73B£6.92B£5.79B£2.83B£4.13B£1.31B£2.94B£2.79B£3.63B£2.7B£291M£1.47B£956M£3.51B£717.64M£2.09B£1.58B£1.45B£1.36B£1.55B£2.13B£2.28B£2.25B£1.32B£1.18B£1.55B£400M£597M£366M£871M£425M£142M£252M£197M£106M
Deferred Revenue £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£1.13B£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0
Other Current Liabilities £2.52B£14.07B£12.99B£13.05B£20.22B£11.28B£8.99B£7.56B£8.15B£7.52B£9.74B£5.62B£3.88B£2.99B£1.98B£5.68B£6.6B£6.43B£6.45B£4.96B£6.54B£6.56B£5.99B£2.65B£2.54B£2.41B£2.34B£1.54B£1.43B£1.04B£1.01B£847M£608M£522M£438M£396M
Total Non-Current Liabilities £34.09B£37.48B£37.28B£31.9B£26.32B£35.12B£31.15B£22.42B£20.6B£20.91B£17.24B£19.69B£20B£21.06B£10.76B£8.64B£10.11B£7.65B£6.9B£3.09B£6.13B£4.12B£3.55B£1.97B£2.43B£2.66B£2.89B£608M£601M£475M£435M£281M£293M£195M£183M£144M
Long-Term Debt £20.57B£23.43B£23.59B£20.27B£14.26B£14.66B£15.32B£15.84B£15.46B£14.67B£12.2B£14.81B£14.79B£15.23B£7.07B£4.77B£5.27B£4.38B£3.65B£3.09B£3.09B£2.11B£1.75B£1.26B£1.8B£1.84B£1.7B£272M£212M£137M£140M£44M£32M£12M£13M£10M
Other Non-Current Liabilities £9.96B£10.43B£9.86B£10.46B£10.66B£18.52B£14.3B£6.13B£4.45B£5.24B£4.22B£4.17B£4.57B£5.11B£2.8B£3.27B£4.28B£2.7B£3.26B£0£2.3B£2B£1.8B£711M£629M£820M£1.19B£206M£196M£159M£154M£154M£208M£150M£142M£129M
Total Debt £24.17B£27.15B£30.51B£26.06B£17.09B£18.79B£16.63B£18.78B£18.25B£18.3B£14.9B£15.1B£16.26B£16.19B£10.58B£5.49B£7.36B£5.96B£5.1B£4.45B£4.64B£4.24B£4.03B£3.51B£3.12B£3.02B£3.25B£672M£809M£503M£1.01B£469M£174M£264M£210M£116M
Total Shareholder Equity £15.05B£14.59B£11.4B£4.36B£-68M£1.12B£5.11B£4.26B£7B£5.81B£8.03B£8.89B£10.01B£7.93B£9.61B£9.38B£7.31B£5.92B£7.71B£34.92B£6.58B£8.4B£8.96B£3.19B£2.77B£1.89B£1.27B£5.15B£4.66B£3.64B£3.28B£2.81B£2.31B£1.8B£1.46B£1.1B
Common Stock £1.35B£1.35B£1.35B£1.34B£1.34B£1.34B£1.34B£1.34B£1.34B£1.35B£1.39B£1.42B£1.42B£1.42B£1.5B£1.5B£1.49B£1.48B£1.49B£0£1.51B£1.55B£1.56B£910M£906M£894M£886M£762M£758M£753M£750M£747M£372M£370M£370M£370M
Retained Earnings £7.94B£6.75B£4.53B£-2.14B£-6.48B£-5.39B£-1.4B£-2.07B£913M£652M£3.37B£4.78B£6.32B£4.62B£6.48B£6.96B£5.58B£4.78B£4.04B£0£2.95B£3.95B£4.28B£0£0£0£0£0£0£0£0£0£0£0£0£0
Accumulated Other Comprehensive Income Loss (AOCL) £0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£0£-5.73B£-5.4B£-4.91B£-2.51B£-2.21B£-1.97B£-1.86B£0£0£0£0£0£0£0£0£0
Other Shareholder Equity £5.76B£6.49B£5.53B£5.15B£5.07B£5.17B£5.17B£5B£4.75B£3.81B£3.27B£2.69B£2.27B£1.89B£1.63B£922.31M£240.6M£-339.41M£2.19B£34.92B£7.86B£8.31B£8.04B£4.79B£4.07B£2.96B£2.24B£4.39B£3.9B£2.89B£2.53B£2.06B£1.94B£1.43B£1.09B£730M
Total Investments £2.21B£3.42B£2.15B£1.56B£1.1B£1.25B£1.46B£1.45B£1.52B£1.37B£1.15B£1.79B£1.35B£1.03B£846M£736M£638M£507M£294M£2.93B£3.12B£0£2.39B£1.81B£1.66B£1.46B£1.01B£2.71B£2.44B£1.74B£2.11B£1.34B£782M£1.19B£963M£603M
Net Debt £19.9B£21.06B£25.8B£22.19B£13.26B£13.89B£10.8B£14.45B£12.71B£14.12B£9.19B£9.04B£9.71B£10.56B£7.2B£3.48B£3.16B£4.8B£4.14B£3.37B£3.59B£3.52B£2.75B£3.29B£2.88B£2.81B£2.98B£617M£746M£479M£977M£203M£-401M£224M£187M£81M
Book Value £21.34B£20.81B£18.36B£3.67B£3.49B£4.96B£8.88B£4.94B£7.81B£6.75B£8.83B£9.74B£10.74B£8.32B£9.92B£9.64B£7.57B£6.2B£8.45B£34.79B£7.39B£8.4B£8.96B£3.19B£2.77B£1.89B£1.27B£5.15B£4.66B£3.64B£3.28B£2.81B£2.31B£1.8B£1.46B£1.1B

Discounted Cash Flow

Use the Discounted Cash Flow (DCF) tool to estimate the intrinsic value of GlaxoSmithKline plc stock.

Assumptions
Forecast Period
Required Return
  Low Mid High
Revenue Growth
FCFE Margin
Perpetual Growth
Terminal P/FCFE
Assumptions

The number of assumptions to make for each forecast.

Forecast Period

The number of years to forecast future cash flows. These future cash flows are used to determine the intrinsic present value for the stock.

It is generally recommended to select a longer period for more established companies with stable financial histories.

Forecast Period

The compounding annual rate of return required, according to your investment objectives. This is used to discount back future cash flows.

Revenue Growth

Estimate the annual compounding revenue growth rate. You can use the historical compounding annual growth rates provided below as a guide.

  • 1 Year 0.04%
  • 3 Years 3.14%
  • 5 Years 4.18%
  • 10 Years 3.32%
Levered Free Cash Flow Margin

Estimate levered free cash flow (FCFE) as a percentage of revenue. You can use the historical margins provided below as a guide.

  • 1 Year 8.87%
  • 3 Years 3.55%
  • 5 Years 6.09%
  • 10 Years 5.71%
Perpetual Growth Rate

Estimate the compounding annual growth rate at which revenues will grow in perpetuity after the forecast period. This is the first method used to calculate the terminal value.

Values of between 2% and 5% are generally recommended.

Price To Levered Free Cash Flow

Estimate the price to levered free cash flow (P/FCFE) for the stock after the forecast period. This is the second method used to calculate the terminal value.

This method for calculating the terminal value can be preferred for shorter forecast periods. You can use the historical rations provided below as a guide.

  • 1 Year 36.46
  • 3 Years 7.31
  • 5 Years 20.41
  • 10 Years 53.13
Chief Executive Officer (CEO) Ms. Emma N. Walmsley
Full-Time Employees 90.1K
Industry Drug Manufacturers—General
Sector Healthcare
Country GB
Website https://www.gsk.com

Copyright © 2022 STOCKROUTINES